Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients

Status Completed

Clinical Trial Summary

Regional anesthesia is a common clinical anesthesia method, and regional anesthesia-assisted sedation play a central role in promoting patient comfort and relieving anxiety. With increasing age, elderly people experience changes in pharmacokinetics and pharmacodynamics and increased drug sensitivity. Ciprofol has advantages in adverse events such as hypotension and respiratory depression. There are fewer studies on the recommended dosage of ciprofol-assisted sedation for intrathecal anesthesia in elderly patients. The aim of study is to identify the median effective dose(ED50) of ciprofol-assisted sedation in elderly patients undergoing spinal anesthesia

Clinical Trial Description

Select the patients who received knee arthroplasty in the Second Hospital of Shanxi Medical University. The patients received a loading dosage of 0.05mg/kg of ciprofol to begin sedation following the completion of intravertebral anesthesia, and the maintenance dose is calculated using the sequential method. Based on the relevant literature and pilot study, 0.2 mg·kg-1·h-1 is selected as initial test dose with a dose gradient of 0.02 mg·kg-1·h-1. The Modified Alertness Sedation Score (MOAA/S ) scores and the bispectral index (BIS) were recorded for patients before administration (T0), 5 min after administration (T1), 10 min after administration (T2), 20 min after administration (T3), 30 min after administration (T4), 45 min after administration (T5), and 60min after administration (T6). If the first patient had ≥ 4 time points with MOAA/A score ≤3 and BIS<85 from T0-T6, the sedation was regarded as satisfactory, then the next patient 's dose of ciprofol was reduced by one level. On the contrary, if the patient's MOAA/S score and BIS at T0-T6 had less than 4 points of MOAA/S ≤3 points and BIS <85, it was regarded as unsatisfactory sedation. The next patient's dose of ciprofol was increased by one level. After 8 crossovers, the trial was terminated. At the same time, the change of vital signs and adverse reactions before and after administration were recorded ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06293131
Study type	Interventional
Source	Second Hospital of Shanxi Medical University
Contact
Status	Completed
Phase	Early Phase 1
Start date	May 29, 2023
Completion date	September 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03399019` - Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia	N/A
Completed	`NCT03220880` - Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Recruiting	`NCT04820205` - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children	N/A
Recruiting	`NCT04549623` - End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography	N/A
Recruiting	`NCT04822064` - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation	N/A
Completed	`NCT01001533` - Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation	N/A
Completed	`NCT01527903` - A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit	Phase 4
Completed	`NCT00747721` - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU	Phase 1
Completed	`NCT00158873` - Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects	Phase 4
Terminated	`NCT00205517` - Sedation and Psychopharmacology in Critical Care	N/A
Recruiting	`NCT04096768` - The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation	Phase 3
Active, not recruiting	`NCT05082623` - The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters	N/A
Suspended	`NCT03285165` - Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients	Phase 2/Phase 3
Active, not recruiting	`NCT04788589` - Sedation and Ventilator Weaning Protocol in PICU	N/A
Completed	`NCT03425474` - Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy	Phase 3
Recruiting	`NCT06061159` - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction	Phase 4
Completed	`NCT06449365` - Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy	Phase 4
Completed	`NCT02171910` - Doxapram as an Additive to Propofol Sedation in Sedation for ERCP	Phase 4
Completed	`NCT02211118` - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD	Phase 4
Completed	`NCT01694745` - EUROpean Pain Audit In Neonates	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms